PTD-DBM Peptide: Hair Growth Research in Mice and Cells
PTD-DBM peptide is a lab-made peptide that blocks the protein CXXC5, a brake on the Wnt/beta-catenin pathway behind hair regrowth. In the 2017 mouse study Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis, it sped up hair regrowth and new hair follicle growth after wounds. No human study exists. The research comes from one group, and its senior author is CEO of the company licensed to develop it.
Sources: PubMed 28595998 (2017); PubMed 36831222 (2023)
Short answer
- Does PTD-DBM regrow hair?
- In mice, yes. In people, it has never been tested.
- Is it approved?
- No. A 2025 review lists it as having no official approval and calls its results preclinical.
- Who is behind the research?
- One group. Its 2023 paper says an author is CEO of CK Regeon, which holds a license to develop the pathway activator.
What PTD-DBM Is Made Of
PTD-DBM is a synthetic peptide built from four working parts. The name spells out the two main ones: a protein transduction domain (PTD) and a Dishevelled binding motif (DBM).
- PTD: a stretch that helps the peptide get into cells.
- Linker: a flexible joint between the parts.
- DBM: the piece that competes with CXXC5 for the protein Dishevelled, which is why the papers call it a competitor peptide.
- Tagged lysine: a lysine joined to the dye FITC so researchers can see where the peptide goes.
That last part matters for anyone reading a product label. The research version carries a lab dye for tracking. The papers describe a research peptide; none of them describes a cosmetic product.
Sources: PMC4493411 (2015); PubMed 36831222 (2023)
The CXXC5 Brake on Hair Growth
The idea behind PTD-DBM is that CXXC5 acts as a brake on hair growth. In 2017 the research group reported that CXXC5 is a negative regulator of the Wnt/beta-catenin pathway involved in hair regrowth, working through its contact with Dishevelled.
Two findings support the brake idea. In samples from human balding scalps, CXXC5 was raised in miniaturized (shrunken) hair follicles and in the arrector pili muscles, the tiny muscles that make hair stand up. And mice bred without the CXXC5 gene regrew hair faster.
These scalp samples are not the only human material in the research. The 2017 study also used human hair follicle dermal papilla cells, and the 2015 wound study looked at human skin cells from acute wounds. But none of this tested the peptide in a living person. It is all tissue samples and lab-grown cells.
Sources: PubMed 28595998 (2017); PubMed 26056233 (2015)
The PTD-DBM Hair Studies
In the hair studies, blocking CXXC5 with the peptide sped up regrowth in mice. The authors present this as a possible treatment target, not a proven treatment.
The 2017 paper reports that breaking the CXXC5 and Dishevelled contact with a competitor peptide switched on the Wnt/beta-catenin pathway. It sped up hair regrowth and the forming of new hair follicles after a wound. The authors conclude that this contact is a potential target for treating hair loss.
The 2023 paper looked at male pattern hair loss, which its title links to DHT acting through a molecule called PGD2. It reports that PGD2 suppressed hair growth, and that this was overcome either by knocking out the Cxxc5 gene or by treatment with PTD-DBM. It also reports that DHT-driven hair loss was eased when both GSK-3 beta and CXXC5 were blocked.
A 2025 review sums up these results. It says applying PTD-DBM to the skin enhanced hair regrowth in mouse models of androgenetic alopecia, and it groups PTD-DBM with GSK3 beta inhibitors as showing the most tangible outcomes in preclinical models.
Sources: PubMed 28595998 (2017); PubMed 36831222 (2023); Review, PMC12153676 (2025)
The Wound Healing Studies
PTD-DBM was first studied for skin wounds, not hair. In lab-grown cells it raised beta-catenin and collagen, and in mice it helped wounds heal when paired with valproic acid.
The 2015 paper reports that PTD-DBM broke a feedback loop driven by CXXC5 and switched on beta-catenin and collagen production in cells. In mice, treating skin wounds with PTD-DBM plus valproic acid, a GSK3 beta inhibitor, sped up healing more than either one did alone.
The full text gives the mouse setup. The wounded skin of 7 week old male C3H mice was treated daily with 100 µM PTD-DBM, with or without valproic acid, for 11 days. That is a lab concentration on mouse skin, not a human dose.
A 2023 study loaded the peptide and valproic acid into a sticky hyaluronic acid gel patch. In that wound model, the patch significantly reduced scar formation during healing.
Sources: PubMed 26056233 (2015); PMC4493411 (2015); PubMed 36854308 (2023)
Every PTD-DBM Study, in Order
Every PTD-DBM study found was done in cells, mice or tissue samples, followed by one review. This timeline shows what each tested.
| Year | Tested on | What was reported |
|---|---|---|
| 2015 | Human skin cells and mouse wounds | Raised beta-catenin and collagen in cells; with valproic acid, healed mouse skin wounds faster than either alone |
| 2017 | Human balding scalp samples and mice | CXXC5 was higher in shrunken follicles; blocking it sped up hair regrowth and new follicle formation after wounding |
| 2023 | Hair loss models driven by PGD2 and DHT | PTD-DBM overcame the block PGD2 put on hair growth; DHT hair loss eased when GSK-3 beta and CXXC5 were both blocked |
| 2023 | Mouse wounds with a gel patch | A hyaluronic acid patch carrying the peptide and valproic acid reduced scar formation |
| 2025 | Review of the field | Topical PTD-DBM improved hair regrowth in mouse models of androgenetic alopecia; still preclinical, no approval |
Sources: PubMed 26056233 (2015); PubMed 28595998 (2017); PubMed 36831222 (2023); PubMed 36854308 (2023); Review, PMC12153676 (2025)
Does Peptide Treatment Work for Hair Growth in People?
For PTD-DBM, nobody knows yet, because it has not been tested in people. A search of PubMed found only lab, mouse and review papers, and ClinicalTrials.gov has no PTD-DBM study.
The 2025 review is plain about the gap. It lists PTD-DBM as having no official approval, and it says the stability and delivery of these treatments in clinical practice remain challenging. A peptide that works on mouse skin in a lab still has to stay stable and reach the follicle in human scalp.
Many shop pages sell PTD-DBM serums. No official source confirms that those products contain the peptide used in the studies, or how much. For hair loss options with human trial data, see our hair loss guide and our review of peptides for hair growth.
Sources: Review, PMC12153676 (2025)
Risks the 2025 Review Flags
There is no human safety data for PTD-DBM. The main risk on record is one the review raises for any therapy that switches on the Wnt/beta-catenin pathway.
The review lists expected off-target effects for this kind of treatment: atypical activation of the pathway, which is associated with colorectal and hepatocellular (liver) carcinomas. That is a warning about the pathway, not a cancer found in a PTD-DBM study. It is still the reason a human safety trial would matter before anyone could say the peptide is safe.
Sources: Review, PMC12153676 (2025)
Who Runs the PTD-DBM Research
All of the PTD-DBM research found comes from one group, and its senior author has a business stake. PubMed lists Choi KY as the last (senior) author of all four PTD-DBM papers. That is a conflict of interest, and the 2023 paper discloses it.
The paper states that K-Y.C. is the CEO of CK Regeon Inc. in Seoul, which has a license to develop and use the Wnt/beta-catenin pathway activator disclosed in the publication. A conflict does not make the results wrong. It does mean no independent lab has yet repeated them.
Sources: PubMed 36831222 (2023)
Common Questions
Does peptide treatment work for hair growth?+
For PTD-DBM, it has only been shown in mice. A 2025 review says applying it to the skin improved hair regrowth in mouse models of androgenetic alopecia, and that PTD-DBM has no official approval. No human study of PTD-DBM for hair was found.
What is PTD-DBM peptide?+
It is a lab-made peptide with a part that helps it enter cells (PTD), a flexible linker, a Dishevelled binding motif (DBM) and a dye-tagged lysine so researchers can see it. It blocks the protein CXXC5 from binding Dishevelled, which switches on the Wnt/beta-catenin pathway.
Has PTD-DBM been tested in humans?+
No. PubMed lists cell, mouse and review papers on PTD-DBM, and ClinicalTrials.gov has no PTD-DBM study. The human-derived work is limited to tissue samples and lab-grown cells, such as balding-scalp samples, human hair follicle dermal papilla cells, and skin cells from human wounds. None of it tested the peptide in a living person.
Is PTD-DBM FDA approved?+
No. A 2025 review lists PTD-DBM as having no official approval, and its results are from mouse models only.
What are the side effects of PTD-DBM?+
Not known in people, because it has not been tested in people. A 2025 review warns that therapies that switch on the Wnt/beta-catenin pathway carry an expected off-target risk: atypical activation of the pathway is associated with colorectal and liver cancers.
Do PTD-DBM hair serums work?+
No study has tested a retail PTD-DBM serum. No official source confirms that these products contain the peptide used in the research, or how much of it. The research used lab-made peptide on mice and cells.
Who developed PTD-DBM?+
The research comes from one group. The 2023 paper states that its author K-Y.C. is the CEO of CK Regeon Inc. in Seoul, which has a license to develop and use the Wnt/beta-catenin pathway activator disclosed in the paper.
Sources: Review, PMC12153676 (2025); PMC4493411 (2015); PubMed 28595998 (2017); PubMed 36831222 (2023)
Related reading
This guide is for educational purposes only and is not medical advice. It describes what published cell, mouse and review papers report about PTD-DBM. PTD-DBM is a research compound with no official approval. Talk to a qualified healthcare professional before making any decision about your health.